Abstract: Macrophages influence anti-tumor immunity through tractable metabolic and checkpoint programs. Within hypoxic, nutrient-competitive tumor beds, tumor-associated macrophages (TAMs) adopt oxidative and lipid-based metabolisms, dampening antigen presentation and T-cell support. Converging evidence shows that lactate flux, fatty acid oxidation (FAO), and glutamine handling steer TAMs toward immunosuppressive states that blunt checkpoint efficacy. Here, we synthesize the mechanism by which discrete pathways—glycolysis/pentose phosphate pathway (PPP) switching, FAO–lysosomal lipolysis, and glutamine–α-ketoglutarate signaling—mechanistically reprogram TAMs. We then map these circuits onto combination strategies involving programmed cell death (ligand) protein 1/cytotoxic T-lymphocyte antigen-4 (PD-(L)1/CTLA-4) blockade, chemotherapy/radiotherapy, and chimeric antigen receptor T-cell (CAR-T). Rather than providing a catalogue, we emphasize when metabolic rewiring dominates, which TAM subsets are affected, and how these levers can be timed or co-inhibited to restore cytotoxic T-cell function. This approach provides operational guidance for pairing macrophage-directed agents with immune checkpoint inhibitors in solid tumors.

巨噬细胞在肿瘤免疫治疗中的作用：代谢、免疫检查点及联合策略

[1]Anami T, Pan C, Fujiwara Y, et al., 2024. Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy. Cancer Sci, 115(1):59-69.

[2]Anderson N, Simon MC, 2020. The tumor microenvironment. Curr Biol, 30(16):R921-R925.

[3]Baardman J, Verberk SGS, Prange KHM, et al., 2018. A defective pentose phosphate pathway reduces inflammatory macrophage responses during hypercholesterolemia. Cell Rep, 25(8):2044-2052.e5.

[4]Binnewies M, Roberts EW, Kersten K, et al., 2018. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 24(5):541-550.

[5]Biswas SK, Mantovani A, 2012. Orchestration of metabolism by macrophages. Cell Metab, 15(4):432-437.

[6]Bourhis M, Palle J, Galy-Fauroux I, et al., 2021. Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. Front Immunol, 12:616837.

[7]Cannarile MA, Weisser M, Jacob W, et al., 2017. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer, 5(1):53.

[8]Cassetta L, Pollard JW, 2020. Tumor-associated macrophages. Curr Biol, 30(6):R246-R248.

[9]Chen DS, Mellman I, 2013. Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1):1-10.

[10]Chen JW, Zhu HD, Yin YH, et al., 2022. Colorectal cancer: metabolic interactions reshape the tumor microenvironment. Biochim Biophys Acta Rev Cancer, 1877(5):188797.

[11]Chen KT, Li XC, Dong SY, et al., 2025. Modulating tumor-associated macrophages through CSF1R inhibition: a potential therapeutic strategy for HNSCC. J Transl Med, 23:27.

[12]Chen XW, Yu TJ, Zhang J, et al., 2017. CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis. Oncogene, 36(35):5045-5057.

[13]Chiba S, Hisamatsu T, Suzuki H, et al., 2017. Glycolysis regulates LPS-induced cytokine production in M2 polarized human macrophages. Immunol Lett, 183:17-23.

[14]Choi Y, Kim SA, Jung H, et al., 2024. Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment. J Immunother Cancer, 12(7):e008864.

[15]Covarrubias AJ, Aksoylar HI, Yu JJ, et al., 2016. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. eLife, 5:e11612.

[16]Croci D, Santalla Méndez R, Temme S, et al., 2022. Multispectral fluorine-19 MRI enables longitudinal and noninvasive monitoring of tumor-associated macrophages. Sci Transl Med, 14(667):eabo2952.

[17]Cui X, Ma C, Vasudevaraja V, et al., 2020. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. eLife, 9:e52253.

[18]de León-Rodríguez SG, Aguilar-Flores C, Gajón JA, et al., 2024. TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response. J Immunother Cancer, 12(7):e008739.

[19]de-Brito NM, Duncan-Moretti J, da-Costa HC, et al., 2020. Aerobic glycolysis is a metabolic requirement to maintain the M2-like polarization of tumor-associated macrophages. Biochim Biophys Acta Mol Cell Res, 1867(2):118604.

[20]Deng L, Stafford JH, Liu SC, et al., 2017. SDF-1 blockade enhances anti-VEGF therapy of glioblastoma and can be monitored by MRI. Neoplasia, 19(1):1-7.

[21]Erlich JR, To EE, Luong R, et al., 2022. Glycolysis and the pentose phosphate pathway promote LPS-induced NOX2 oxidase- and IFN-β-dependent inflammation in macrophages. Antioxidants, 11(8):1488.

[22]Fan GY, Xie TJ, Li L, et al., 2024. Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. npj Precis Oncol, 8:75.

[23]Fujiwara T, Yakoub MA, Chandler A, et al., 2021. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther, 20(8):1388-1399.

[24]Galluzzi L, Buqué A, Kepp O, et al., 2017. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol, 17(2):97-111.

[25]Gao C, Cheng KM, Li Y, et al., 2022. Injectable immunotherapeutic hydrogel containing RNA-loaded lipid nanoparticles reshapes tumor microenvironment for pancreatic cancer therapy. Nano Lett, 22(22):8801-8809.

[26]Gao J, Liang YZ, Wang L, 2022. Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol, 13:888713.

[27]Hilt ZT, Morrell CN, 2020. Essential amino acids—essential in arterial thrombosis. Circulation, 142(1):65-67.

[28]Homicsko K, Zygoura P, Norkin M, et al., 2023. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma. J Immunother Cancer, 11(10):e007585.

[29]Hou SY, Zhao YC, Chen JJ, et al., 2024. Tumor-associated macrophages in colorectal cancer metastasis: molecular insights and translational perspectives. J Transl Med, 22:62.

[30]Huang SCC, Everts B, Ivanova Y, et al., 2014. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol, 15(9):846-855.

[31]Huang SCC, Smith AM, Everts B, et al., 2016. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity, 45(4):817-830.

[32]Huang Y, Xie Y, Zhang YQ, et al., 2025. Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC. Mol Cancer, 24:177.

[33]Jelinic P, Ricca J, van Oudenhove E, et al., 2018. Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade. J Natl Cancer Inst, 110(7):787-790.

[34]Jha AK, Huang SCC, Sergushichev A, et al., 2015. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity, 42(3):419-430.

[35]Jia SY, Bode AM, Chen X, et al., 2024. Unlocking the potential: targeting metabolic pathways in the tumor microenvironment for cancer therapy. Biochim Biophys Acta Rev Cancer, 1879(5):189166.

[36]Jian H, Wang XB, Song PP, et al., 2022. Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer. Acta Biomater, 140:518-529.

[37]Jin XH, Zhang N, Yan TH, et al., 2025. Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential. Front Immunol, 16:1573039.

[38]Jing WQ, Guo X, Wang GY, et al., 2020. Breast cancer cells promote CD169⁺ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. Int Immunopharmacol, 78:106012.

[39]Kennel KB, Greten FR, 2021. Immune cell-produced ROS and their impact on tumor growth and metastasis. Redox Biol, 42:101891.

[40]Kim Y, Lee S, Jon S, 2024. Liposomal delivery of an immunostimulatory CpG induces robust antitumor immunity and long-term immune memory by reprogramming tumor-associated macrophages. Adv Healthc Mater, 13(6):2300549.

[41]Kuang J, Rao ZY, Zheng DW, et al., 2023. Nanoparticles hitchhike on monocytes for glioblastoma treatment after low-dose radiotherapy. ACS Nano, 17(14):13333-13347.

[42]Lee Y, Bogdanoff D, Wang YT, et al., 2021. XYZeq: spatially resolved single-cell RNA sequencing reveals expression heterogeneity in the tumor microenvironment. Sci Adv, 7(17):eabg4755.

[43]Li QY, Zhang XY, Ke RQ, 2022. Spatial transcriptomics for tumor heterogeneity analysis. Front Genet, 13:906158.

[44]Li WQ, Yuan Q, Li M, et al., 2024. Research advances on signaling pathways regulating the polarization of tumor-associated macrophages in lung cancer microenvironment. Front Immunol, 15:1452078.

[45]Li Z, Yu QJ, Zhu QY, et al., 2022. Applications of machine learning in tumor-associated macrophages. Front Immunol, 13:985863.

[46]Liao ZX, Ou DL, Hsieh MJ, et al., 2021. Synergistic effect of repolarization of M2 to M1 macrophages induced by iron oxide nanoparticles combined with lactate oxidase. Int J Mol Sci, 22(24):13346.

[47]Lin H, Wei S, Hurt EM, et al., 2018. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. J Clin Invest, 128(2):805-815.

[48]Lin JY, Liu YH, Liu PY, et al., 2023. SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res, 42:339.

[49]Lin WW, Luo YK, Wu J, et al., 2023. Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment. J Immunother Cancer, 11(11):e007402.

[50]Liu C, Xie JD, Lin B, et al., 2024. Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy. Adv Sci, 11(23):2401061.

[51]Liu MG, O’Connor RS, Trefely S, et al., 2019. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47–mediated ‘don’t-eat-me’ signal. Nat Immunol, 20(3):265-275.

[52]Liu PS, Wang HP, Li XY, et al., 2017. α-Ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol, 18(9):985-994.

[53]Liu Q, Yang CG, Wang SY, et al., 2020. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. Cell Commun Signal, 18:51.

[54]Liu YT, Zugazagoitia J, Ahmed FS, et al., 2020. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res, 26(4):970-977.

[55]Lu YJ, Sun QK, Guan QF, et al., 2023. The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma. J Hepatol, 79(5):1172-1184.

[56]Lyu A, Fan ZH, Clark M, et al., 2025. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature, 637(8048):1207-1217.

[57]Magkouta SF, Vaitsi PC, Pappas AG, et al., 2021. CSF1/CSF1R axis blockade limits mesothelioma and enhances efficiency of anti-PDL1 immunotherapy. Cancers, 13(11):2546.

[58]Mantovani A, Biswas SK, Galdiero MR, et al., 2013. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol, 229(2):176-185.

[59]Martinez-Usatorre A, Kadioglu E, Boivin G, et al., 2021. Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Sci Transl Med, 13(606):eabd1616.

[60]Meng J, Li L, Xu Y, et al., 2023. A simple liposome-based bionic bacterium for tumor treatment by re-education of tumor-associated microphages in combination with chemotherapy. Colloids Surf B Biointerfaces, 222:113069.

[61]Menga A, Serra M, Todisco S, et al., 2020. Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. EMBO Mol Med, 12(10):e11210.

[62]Menga A, Favia M, Spera I, et al., 2021. N‐Acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages. EMBO Rep, 22(9):e51981.

[63]Mondini M, Loyher PL, Hamon P, et al., 2019. CCR2-dependent recruitment of Tregs and monocytes following radiotherapy is associated with TNFα-mediated resistance. Cancer Immunol Res, 7(3):376-387.

[64]Negrea G, Rauca VF, Meszaros MS, et al., 2022. Active tumor-targeting nano-formulations containing simvastatin and doxorubicin inhibit melanoma growth and angiogenesis. Front Pharmacol, 13:870347.

[65]Niu ZY, Shi Q, Zhang WL, et al., 2017. Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs. Nat Commun, 8:766.

[66]Oh MH, Sun IH, Zhao L, et al., 2020. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest, 130(7):3865-3884.

[67]Ohradanova-Repic A, Machacek C, Charvet C, et al., 2018. Extracellular purine metabolism is the switchboard of immunosuppressive macrophages and a novel target to treat diseases with macrophage imbalances. Front Immunol, 9:852.

[68]Ostuni R, Kratochvill F, Murray PJ, et al., 2015. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol, 36(4):229-239.

[69]Owaki T, Iida T, Miyai Y, et al., 2024. Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade. Br J Cancer, 131(2):372-386.

[70]Palmieri EM, Menga A, Martín-Pérez R, et al., 2017. Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis. Cell Rep, 20(7):1654-1666.

[71]Park DJ, Sung PS, Lee GW, et al., 2021. Preferential expression of programmed death ligand 1 protein in tumor-associated macrophages and its potential role in immunotherapy for hepatocellular carcinoma. Int J Mol Sci, 22(9):4710.

[72]Peckert-Maier K, Langguth P, Strack A, et al., 2023. CD83 expressed by macrophages is an important immune checkpoint molecule for the resolution of inflammation. Front Immunol, 14:1085742.

[73]Peranzoni E, Lemoine J, Vimeux L, et al., 2018. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proc Natl Acad Sci USA, 115(17):E4041-E4050.

[74]Petty AJ, Li A, Wang XY, et al., 2019. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8⁺ T cell recruitment. J Clin Invest, 129(12):5151-5162.

[75]Petty AJ, Dai R, Lapalombella R, et al., 2021. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8⁺ T cell function. JCI Insight, 6(6):e146707.

[76]Plotkin DL, Delcastillo K, van Every DW, et al., 2021. Isolated leucine and branched-chain amino acid supplementation for enhancing muscular strength and hypertrophy: a narrative review. Int J Sport Nutr Exerc Metab, 31(3):292-301.

[77]Praharaj M, Shen F, Lee AJ, et al., 2024. Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancers. Cancer Immunol Res, 12(7):854-875.

[78]Raines LN, Zhao HX, Wang YZ, et al., 2022. PERK is a critical metabolic hub for immunosuppressive function in macrophages. Nat Immunol, 23(3):431-445.

[79]Ravi M, Paramesh V, Kaviya SR, et al., 2015. 3D cell culture systems: advantages and applications. J Cell Physiol, 230(1):16-26.

[80]Reinfeld BI, Madden MZ, Wolf MM, et al., 2021. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature, 593(7858):282-288.

[81]Rongvaux A, Willinger T, Martinek J, et al., 2014. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol, 32(4):364-372.

[82]Roux C, Jafari SM, Shinde R, et al., 2019. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci USA, 116(10):4326-4335.

[83]Saqib J, Park B, Jin Y, et al., 2023. Identification of niche-specific gene signatures between malignant tumor microenvironments by integrating single cell and spatial transcriptomics data. Genes, 14(11):2033.

[84]Sato T, Sugiyama D, Koseki J, et al., 2025. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages. JCI Insight, 10(1):e178146.

[85]Shao N, Qiu H, Liu J, et al., 2025. Targeting lipid metabolism of macrophages: a new strategy for tumor therapy. J Adv Res, 68:99-114.

[86]Sharma G, Ojha R, Noguera-Ortega E, et al., 2020. PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma. JCI Insight, 5(17):e133225.

[87]Shen WH, Liu T, Pei P, et al., 2022. Metabolic homeostasis-regulated nanoparticles for antibody-independent cancer radio-immunotherapy. Adv Mater, 34(51):2207343.

[88]Shimizu D, Yuge R, Kitadai Y, et al., 2024. Pexidartinib and immune checkpoint inhibitors combine to activate tumor immunity in a murine colorectal cancer model by depleting M2 macrophages differentiated by cancer-associated fibroblasts. Int J Mol Sci, 25(13):7001.

[89]Shimoyama S, Okada K, Kimura T, et al., 2023. FF-10850, a novel liposomal topotecan achieves superior antitumor activity via macrophage- and ammonia-mediated payload release in the tumor microenvironment. Mol Cancer Ther, 22(12):1454-1464.

[90]Singh S, Lee N, Pedroza DA, et al., 2022. Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. Cancer Res, 82(12):2281-2297.

[91]Song N, Cui K, Zeng LQ, et al., 2024. Advance in the role of chemokines/chemokine receptors in carcinogenesis: focus on pancreatic cancer. Eur J Pharmacol, 967:176357.

[92]Stack EC, Wang CC, Roman KA, et al., 2014. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods, 70(1):46-58.

[93]Stöth M, Freire Valls A, Chen MY, et al., 2019. Splenectomy reduces lung metastases and tumoral and metastatic niche inflammation. Int J Cancer, 145(9):2509-2520.

[94]Su P, Wang Q, Bi EG, et al., 2020. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res, 80(7):1438-1450.

[95]Sui DZ, Liang KF, Gui YX, et al., 2022. Optimization design of sialic acid derivatives enhances the performance of liposomes for modulating immunosuppressive tumor microenvironments. Life Sci, 310:121081.

[96]Tan Z, Xie N, Cui HC, et al., 2015. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol, 194(12):6082-6089.

[97]Tang JH, Ming L, Qin FY, et al., 2024. The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients. Immunobiology, 229(3):152805.

[98]Tartey S, Neale G, Vogel P, et al., 2021. A MyD88/IL1R axis regulates PD-1 expression on tumor-associated macrophages and sustains their immunosuppressive function in melanoma. Cancer Res, 81(9):2358-2372.

[99]Tavakoli S, Downs K, Short JD, et al., 2017. Characterization of macrophage polarization states using combined measurement of 2-deoxyglucose and glutamine accumulation: implications for imaging of atherosclerosis. Arterioscler Thromb Vasc Biol, 37(10):1840-1848.

[100]Tharp KM, Kersten K, Maller O, et al., 2024. Tumor-associated macrophages restrict CD8⁺ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat Cancer, 5(7):1045-1062.

[101]Tsai TL, Zhou TA, Hsieh YT, et al., 2022. Multiomics reveal the central role of pentose phosphate pathway in resident thymic macrophages to cope with efferocytosis-associated stress. Cell Rep, 40(2):111065.

[102]Tsuruta A, Shiiba Y, Matsunaga N, et al., 2022. Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice. Mol Cancer Res, 20(6):972-982.

[103]Voissière A, Gomez-Roca C, Chabaud S, et al., 2024. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Sci Transl Med, 16(731):eadd1834.

[104]Wainberg ZA, Eisenberg PD, Sachdev JC, et al., 2016. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. J Clin Oncol, 34(S4):TPS465.

[105]Wan C, Sun YJ, Tian Y, et al., 2020. Irradiated tumor cell–derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv, 6(13):eaay9789.

[106]Wang HG, Yung MMH, Ngan HYS, et al., 2021. The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression. Int J Mol Sci, 22(12):6560.

[107]Wang XD, Zhang SL, Xue DX, et al., 2025. Metabolic reprogramming of macrophages in cancer therapy. Trends Endocrinol Metab, 36(7):660-676.

[108]Wei F, Wang D, Wei JY, et al., 2021. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cell Mol Life Sci, 78(1):173-193.

[109]Wei ZH, Zhang XQ, Yong TY, et al., 2021. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat Commun, 12:440.

[110]Wen ZW, Sun HY, Zhang ZH, et al., 2023. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Cancer Commun, 43(5):562-581.

[111]Wu SZ, Al-Eryani G, Roden DL, et al., 2021. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet, 53(9):1334-1347.

[112]Xiao BJ, Li GJ, Gulizeba H, et al., 2024. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation. J Transl Med, 22:442.

[113]Xu C, Xia Y, Zhang BW, et al., 2023. Macrophages facilitate tumor cell PD-L1 expression via an IL-1β-centered loop to attenuate immune checkpoint blockade. MedComm, 4(2):e242.

[114]Xu LJ, Li BY, Pi CY, et al., 2022. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade. J Immunother Cancer, 10(12):e005447.

[115]Xu SM, Wang CY, Yang LG, et al., 2023. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Front Immunol, 14:1199631.

[116]Yan HL, Shi JH, Dai Y, et al., 2022. Technique integration of single-cell RNA sequencing with spatially resolved transcriptomics in the tumor microenvironment. Cancer Cell Int, 22:155.

[117]Yang H, Kim C, Zou WP, 2024. Metabolism and macrophages in the tumor microenvironment. Curr Opin Immunol, 91:102491.

[118]Yang LF, Venneti S, Nagrath D, 2017. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng, 19:163-194.

[119]Zeng WT, Li F, Jin SK, et al., 2023. Functional polarization of tumor-associated macrophages dictated by metabolic reprogramming. J Exp Clin Cancer Res, 42:245.

[120]Zhang N, Liu CH, Jin L, et al., 2020. Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 tumor-associated macrophage phenotype in a mouse model of colon cancer. J Agric Food Chem, 68(40):11182-11196.

[121]Zhao K, Shi RC, Miao HM, 2021. A review of the lipid metabolism reprogramming in tumor associated macrophages. J Sichuan Univ (Med Sci), 52(1):45-49 (in Chinese).

[122]Zhao X, Ren T, Li SJ, et al., 2024. A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells. Int J Biol Sci, 20(13):5109-5126.

[123]Zhen XY, Li YJ, Yuan WQ, et al., 2024. Biointerface-engineered hybrid nanovesicles for targeted reprogramming of tumor microenvironment. Adv Mater, 36(41):2401495.

[124]Zhou W, Hu GL, He JL, et al., 2022. SENP1-Sirt3 signaling promotes α-ketoglutarate production during M2 macrophage polarization. Cell Rep, 39(2):110660.

[125]Zhu NC, Chen SJ, Jin Y, et al., 2024. Enhancing glioblastoma immunotherapy with integrated chimeric antigen receptor T cells through the re-education of tumor-associated microglia and macrophages. ACS Nano, 18(17):11165-11182.

[126]Zhu Y, Yang J, Xu D, et al., 2019. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut, 68(9):1653-1666.

[127]Zuo B, Li T, Liu XY, et al., 2023. Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer. Clin Transl Oncol, 25(11):3188-3202.